Psoriasis - Identifying and Commercializing First-in-Class Innovation, New Report Launched

Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation in first-in-class molecules, including novel angiogenic drugs, growth factors, chaperone proteins and cytokines, according to  Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation report.

This report states that first-in-class programs constitute an estimated 27% of the entire psoriasis pipeline, and are predominantly composed of targeted therapies, including cytokine and receptor modulators, nuclear receptor modulators and intracellular kinase inhibitors.

Senior Analyst says: “There are several novel therapies targeting first-in-class T cell antigens, thanks to a growing understanding of the signaling pathways underlying the psoriasis pathophysiology, in which T cells have been shown to play a substantial role in disease progression.”

Therapies that can selectively modulate specific subsets of immune cells, without compromising the entire immune system, have become increasingly desirable, according to Publisher. One such program is Tregalizumab, a humanized Cluster of Differentiation (CD) 4-specific monoclonal antibody.

Senior Analyst says: “In contrast to other anti-CD4 antibodies, Tregalizumab is able to activate the suppressive properties of regulatory T cells. It is currently in Phase II clinical trials for the treatment of rheumatoid arthritis and in Preclinical development for treating psoriasis.”

Publisher states that although no preclinical or clinical efficacy data has been disclosed for the antibody, it has been involved in a lucrative co-development deal worth $480 million between Biotest and Abbott Laboratories.

Other promising psoriasis therapies are targeting novel angiogenic signaling molecules at the psoriatic plaque level, as topical therapies. This has been validated in a small scale, double-blind and randomized clinical study, according to Publisher.

“With further validation in larger scale clinical studies, insulin receptor substrate-1 inhibitors may prove to be a novel localized therapy for psoriasis, which can be used in conjunction with systemic treatments,” Zhuang concludes.

Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

See Table of contents & Purchase this publication at: - http://mrr.cm/Zmc